Biomarkers in Clinical Development Market Intelligence

Are you looking for answers on Biomarkers in Clinical Development category?

Are you looking for answers on Biomarkers in Clinical Development category?

  • What are the key trends in Biomarkers in Clinical Development category?
  • Am I paying the right price?
  • Am I working with the right supplier?
  • What are the major challenges and risks in Biomarkers in Clinical Development industry?
  • How is Biomarkers in Clinical Development industry performing?

Over 50,000+ users trust Beroe

Report Coverage

  • Global Biomarker Market by Region
  • Global Biomarker Market by Technology (2017)
  • Global Biomarker Market: By Therapeutic Area (2017)
  • Engagement Model in Percentage (2016–2017)

Market Size

Global Market Size

$29 Bn

CAGR

13-14 Percent

Table of contents

  1. Biomarkers in Clinical Development Executive Summary
  2. Executive Summary: Biomarker Market Snapshot
  3. Brexit Impact Update
  1. Biomarkers in Clinical Development Market Analysis
  2. Biomarker Market Overview
  3. SWOT Analysis
  4. Recent Developments
  5. Biomarker Databases
  6. List of Biomarker
  1. Biomarkers in Clinical Development Supply Market Overview
  2. Functional Capabilities
  1. Biomarkers in Clinical Development Sourcing Practices
  2. Sourcing Model
  3. Engagement Models
  1. Biomarkers in Clinical Development
  2. Deals between Buyers and Suppliers
  1. Biomarkers in Clinical Development Quick Reference
  2. Glossary
  3. Expert Profiles

Want a more detailed personalised report?

Global Market Outlook on Biomarkers in Clinical Development

The market growth is mainly driven by factors, such as increasing diagnostic applications of biomarkers, rise in R&D funding from the government, growing number of CROs, low cost of clinical trials in the developing countries, high prevalence and incidence of chronic diseases, and new initiatives for biomarker research

academic-collaborations-global-market-siz

  • Biomarkers are important for predicting prognosis and selecting dose regimes. They are helpful for detecting therapeutic advances and adverse responses as well as for patient stratification, based on efficacy or safety prediction
  • Biomarkers are essential tools for the selection of appropriate patients for treatment with certain drugs, and so enables personalized medicine to a greater extent
  • Biomarker information is also included in labelling, in case of negative selection (i.e., if the biomarker is used to select a population unlikely to respond) or in case of uncertainty about the value of the biomarker, but where a negative selection is suspected, e.g., vandetani
  • Genomics-based biomarker platform is the fastest growing and heavily adopted technology among others. In fact, the genomics biomarker market is expected to grow at a CAGR of ~25–26 percent in the next five years
  • Proteomics biomarker discovery, albeit more complex, is expected to grow at a CAGR of 12–14 percent
  • Imaging biomarkers are expected to grow at a steady rate of 14–15 percent over the next five years
  • The omics family is constantly growing and adding new members, such as genomics, proteomics, peptidomics, and the newer ones, such as epigenomics, transcriptomics, metabolomics, lipidomics, pharmacogenomics, interactomics, and chronemics

Biomarker Market

Cancer

  • The cancer biomarker market is expected to grow at a CAGR of 15 to 15.5 percent
    The market share of cancer biomarkers is expected to reach $ 32,632.11 million by 2024

The growth factors include:

–Increasing rate of cancer patients

–Technological advancement of omics

–Need for personalized cancer treatments

–Rise in the government funding for cancer research

  • Among the regions, Asia–Pacific will continue to grow in the next five years

Cardiovascular

  • Cardiovascular disorders is expected to grow at the highest CAGR of 15.9 percent and is expected to reach $ 25,063.53 million by 2024
  • Cardiac biomarkers are used as risk stratification for various CVDs, such as myocardial infraction, congestive heart failure, ACS, etc.
  • Some of the widely used biomarkers for CVDs as an integrated diagnostic approach include CK-MB, troponin I and T, myoglobin, BNPs, and IMA

Drivers and Restraints

Drivers

  • Increasing diagnostic applications of biomarkers

−Personalized medicine, an emerging practice of medicine that uses an individual's enetic profile to guide decisions made, in regard to the diagnosis, prevention, and treatment of diseases.

−Companion diagnostics involves the use of biomarkers that provides biological and/or clinical information that enables better decision making about the development and use of a potential drug therapy

  • Increasing R&D funding for pharma and biotech companies
  • Non-invasive biomarkers can help in decision making during interim analysis in protocols
  • Accuracy in result - Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages
  • Increasing number of CROs and low cost of clinical trials in developing countries
  • Multi-marker Application: Combination of markers used in the care, along the entire spectrum of disease, by improving screening, simplifying diagnosis, clarifying prognosis, and tailoring treatment
  • Gene-level diagnosis: Cancer diagnosis is becoming more easier with the incorporation of molecular markers, such as DNA, RNA, micro RNAs, and proteins

Restraints

  • High capital investment and low cost-benefit ratio
  • Poorly suited regulatory and reimbursement systems
  • Technical issues related to sample collection and storage
  • Government regulation and ethical problems
  • Complex process

Complimentary 12-month access to Beroe LiVE

Any more questions?

Get in touch with us quickly and easily.